Clinical Trials Patients Pets 
Cannabis Law Report
OCTOBER 2, 2021
The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. The right candidate will have a passion for clinical research in novel therapeutics and a proven track record of regulatory affairs experience. Pet Insurance.
Cannabis Law Report
NOVEMBER 19, 2021
It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Team leadership : mentor European study teams in overall regulatory strategy and compliance to enable future patient access expeditiously.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NORML
JANUARY 18, 2019
House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. At the state level, patients in Ohio and Oklahoma now have access to medical cannabis, as sales began in both states this week. Additionally, a bipartisan coalition of U.S.
CannaMD
MAY 12, 2021
” states: A growing body of basic and clinical research indicates that the endocannabinoid system (ECS) plays a role in anxiety, fear, and repetitive behaviors. In another clinical study , young women suffering from anorexia nervosa received four-week administration of synthetic THC. Do you have questions about medical marijuana?
Cannabis Law Report
APRIL 21, 2022
Commercialization & Patient Access · Any City, Any State, California. It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine and profiled on the front page of The New York Times. Pet Insurance. Employer funded SEP-IRA.
Cannabis Law Report
NOVEMBER 19, 2021
It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Pet Insurance. MAPS PBC is a Public Benefit Corporation, with a dual mandate to generate shareholder value and public benefit.
The Blunt Truth
DECEMBER 23, 2020
Two of the letters also concern CBD products illegally marketed for pets, including a product for use in the eye. It is critical that the FTC take steps to prevent exploitation of patients seeking treatment for substance use disorders.” In its announcement of the warning letters, FDA Principal Deputy Commissioner Amy Abernethy, M.D.,
Expert insights. Personalized for you.
52 
Let's personalize your content